IC
TARS icon

Ikarian Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Ikarian Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$3.63M – 152
2024
Q1 		$3.63M Hold
100,000
– – 0.4% 64
2023
Q4 		$2.02M Buy
+100,000
New +$1.67M 0.19% 85

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital's TARS Position: Q2 2026 in Review

Ikarian Capital held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 31,166 shares worth $1.96M. The position accounts for 0.21% of the portfolio, ranked #89.

Ikarian Capital first reported a position in TARS in Q3 2023 and has held it in 12 quarters since. The position peaked at $33.9M in Q3 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Ikarian Capital held 31,166 shares of Tarsus Pharmaceuticals worth $1.96M as of Q2 2026.
  • Ikarian Capital left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up 0.21% of Ikarian Capital's portfolio in Q2 2026, its #89 holding.
  • Ikarian Capital first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Ikarian Capital's Tarsus Pharmaceuticals position peaked at $33.9M in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.